Trimt - Leading the way in radiopharmaceutical innovation
 

About Trimt - Who we are, where we are.

Founded in 2021 in Radeberg, Saxony, TRIMT GmbH is a science-driven biotechnology company specializing in the development of innovative integrin-targeted radiopharmaceuticals for precision oncology.Built on a strong foundation of scientific expertise and entrepreneurial innovation, TRIMT has developed a proprietary cyclopeptide platform targeting the integrins αvβ6 and αvβ8. Its portfolio includes investigational diagnostic and therapeutic compounds such as Trivehexin, Therahexin, and Triveoctin, with the potential to advance molecular imaging and targeted radionuclide therapy.

Founded by experienced scientists, TRIMT combines interdisciplinary collaboration, creative thinking, and a commitment to translating scientific discoveries into meaningful medical innovations. Since joining ABX in September 2026, TRIMT's technology and expertise have become part of a broader effort to advance next-generation theranostics, supported by ABX's capabilities in clinical development, manufacturing, and global supply. 

Our mission is to push the boundaries of radiopharmaceutical innovation and contribute to better diagnostic and therapeutic options for patients worldwide. 

What we do, and why.

TRIMT‘s Pipeline is widely orthogonal to mainstream research, granting leadership in our market sector.

The global market for radio-theranostics is expected to grow substantially.

TRIMT is committed to driving innovation and advancement in theranostics with a combination of unique technologies.
CompoundTarget, ApplicationPreclinicalTranslationClinical
Trivehexin
αvβ6 Integrin, Dx (PET)
Therahexin
αvβ6 Integrin, Tx (RLT)
Technehexin
αvβ6 Integrin, Dx (SPECT)
Triveoctin
αvβ8 Integrin, Dx (PET)
LPDL1
PD-L1, Dx (PET)
Undisclosed
αvβ6 Integrin, Dx (PET)